Since 2020, COVID-19 has surged across the nation and the world. With variants like Omicron, Delta, Alpha and more, this ...

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 ...

Nirmatrelvir-ritonavir effectively lowers hospitalization rates and long COVID symptoms in non-hospitalized, high-risk patients with mild to moderate COVID-19.

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...

In late August, in time for the fall season, the Food and Drug Administration authorized and approved updated COVID-19 ...

This new study investigated the impact of COVID-19 on patients with myasthenia gravis, finding that although most patients did not experience severe COVID-19, a significant portion suffered ...

The 2024–2025 COVID-19 vaccines are recommended for everyone aged 6 months and older in the US to target the currently circulating SARS-CoV-2 strains, JN.1 and KP.2.

The report, riddled with lies and misinformation, is a crude justification for the subordination of public health and lives ...

LOGAN - According to the Centers for Disease Control (CDC), currently the dominant COVID variant nationwide is KP.3.1 which ...

By Jack Phillips Contributing Writer Recent estimates published by the U.S. Centers for Disease Control and Prevention show ...

A 14-day course of the oral anti-inflammatory drug montelukast didn't shorten symptom duration in nonhospitalized US adults with mild or moderate COVID-19, finds a randomized controlled clinical trial ...